About US
Contact us
-
AstraZeneca R&D chiefs talk roxadustat trial, Ultomiris threats and Imfinzi wingman treme’s futureAstraZeneca’s R&D expense swelled 59% in 2021 to nearly $10 billion. The acquisition of Alexion contributed some, and a mid-stage cull related to the buyout of Ardea Biosciences also cost the com2022/2/11
-
Teva CEO says company could pay up to $3.6B to put opioid litigation to bed: reportTeva could shell out as much as $3.6 billion in cash and meds to settle thousands of opioid lawsuits, Reuters reports. CEO Kåre Schultztoldthe news outlet Teva would likely pay $2.7 billion to $3.6 b2022/2/11
-
Bayer poaches GlaxoSmithKline exec to lead expanding oncology business—including a blockbuster hopefulOncology is hardly what Bayer is known for. But the German drugmaker has raided GlaxoSmithKline—which is itself reestablishing a cancer foothold—for a new leader in the field. Christine R2022/2/8
-
FDA probes TG Therapeutics' Ukoniq over potential for elevated death risks 1 year after drug's approvalHyped as a safer version of other drugs in its class upon its approval last February, TG Therapeutics’ Ukoniqappearedon its way to differentiating itself in certain types of lymphoma. But a year late2022/2/8
-
Novo Nordisk's Wegovy, hamstrung by Catalent FDA write-up, could correct course by mid-2022: analystsWorry not, Wegovy fans: There’s reason to believe supply of Novo Nordisk’s obesity med could resume as planned by the middle of the year. That’s according to Jefferies analysts’ chat with a manufactu2022/1/29
-
What competition? Vertex touts Trikafta's competitive edge on back of strong 2021Vertex finished out 2021 strong, smashing analyst’s sales expectations for the full year. Chalk it up to the company’s entrenched position in cystic fibrosis, where Vertex expects to maintain its lea2022/1/29
-
Pfizer in Texas showdown: Court hearing this week will decide if it can assist FDA in providing COVID documentsTexas federal judge Mark Pittman willconducta hearing on Friday to consider whether to allow Pfizer to participate in the redaction and release of information about the development of its COVID-19 va2022/1/27
-
Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headacheA recent report from Korea buzzed a Biogen takeover by Samsung. Turns out, Samsung is indeed buying something of Biogen’s, just not the entire company that’s saddled with the Alzheimer’s disease drug2022/1/27
-
Gilead's Veklury expands FDA nod to patients outside the hospital as oral version heads to trialGilead Sciences’ Veklury, the first FDA-approved COVID-19 treatment, has extended its reach to patients outside the hospital at a time when effective therapies against omicron are in high demand.2022/1/25
-
With omicron on the prowl, FDA extends inspection pause into FebruaryThe pandemic continues to drag on the FDA’s inspection plans. Now, the regulator is prolonging an intermission that kicked off just before the new year and was pegged to conclude last week.2022/1/25